OK Biotech Co (TPE:4155) Piotroski F-Score: 5 (As of Jun. 27, 2026) — Near Median


TPE:4155 OK Biotech Co Ltd TPE:4155
61 GF Score
Price NT$14.45
GF Value NT$27.27
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is OK Biotech Co Piotroski F-Score?

OK Biotech Co TPE:4155 -3.67% 61 Piotroski F-Score is 5 as of Jun. 27, 2026, which is at its 10-year median of 5.00. GuruFocus rates TPE:4155 with a GF Score™ of 61/100 and a GF Value™ of NT$27.27 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, OK Biotech Co ranks better than 64.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OK Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for OK Biotech Co's Piotroski F-Score or its related term are showing as below:

TPE:4155' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of OK Biotech Co was 7. The lowest was 3. And the median was 5.

OK Biotech Co  (TPE:4155) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OK Biotech Co Piotroski F-Score Related Terms


OK Biotech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for OK Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OK Biotech Co Piotroski F-Score Chart

OK Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 7.00 4.00 4.00 5.00

OK Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 7.00 4.00 6.00 5.00

TPE:4155 vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, OK Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OK Biotech Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where OK Biotech Co's Piotroski F-Score falls into.


TPE:4155
61GF Score
OK Biotech Co Ltd TPE:4155
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 24.794 + -81.075 + 85.186 + 53.544 = NT$82 Mil.
Cash Flow from Operations was 35.262 + -15.979 + 47.738 + 251.839 = NT$319 Mil.
Revenue was 412.374 + 426.756 + 379.583 + 337.582 = NT$1,556 Mil.
Gross Profit was 103.858 + 99.686 + 132.466 + 93.241 = NT$429 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(3695.319 + 3818.143 + 3668.823 + 3893.326 + 3849.424) / 5 = NT$3785.007 Mil.
Total Assets at the begining of this year (Dec24) was NT$3,695 Mil.
Long-Term Debt & Capital Lease Obligation was NT$697 Mil.
Total Current Assets was NT$1,249 Mil.
Total Current Liabilities was NT$548 Mil.
Net Income was 36.102 + 42.269 + -24.239 + 39.843 = NT$94 Mil.

Revenue was 352.277 + 438.764 + 458.272 + 420.72 = NT$1,670 Mil.
Gross Profit was 41.177 + 99.711 + 27.947 + 106.82 = NT$276 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(3067.358 + 3114.957 + 3552.481 + 3428.458 + 3695.319) / 5 = NT$3371.7146 Mil.
Total Assets at the begining of last year (Dec23) was NT$3,067 Mil.
Long-Term Debt & Capital Lease Obligation was NT$356 Mil.
Total Current Assets was NT$1,473 Mil.
Total Current Liabilities was NT$745 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OK Biotech Co's current Net Income (TTM) was 82. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OK Biotech Co's current Cash Flow from Operations (TTM) was 319. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=82.449/3695.319
=0.02231174

ROA (Last Year)=Net Income/Total Assets (Dec23)
=93.975/3067.358
=0.03063712

OK Biotech Co's return on assets of this year was 0.02231174. OK Biotech Co's return on assets of last year was 0.03063712. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OK Biotech Co's current Net Income (TTM) was 82. OK Biotech Co's current Cash Flow from Operations (TTM) was 319. ==> 319 > 82 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=697.226/3785.007
=0.18420732

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=355.767/3371.7146
=0.10551516

OK Biotech Co's gearing of this year was 0.18420732. OK Biotech Co's gearing of last year was 0.10551516. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1249.253/547.601
=2.28131979

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=1472.665/744.764
=1.97735793

OK Biotech Co's current ratio of this year was 2.28131979. OK Biotech Co's current ratio of last year was 1.97735793. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OK Biotech Co's number of shares in issue this year was 154.193. OK Biotech Co's number of shares in issue last year was 146.944. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=429.251/1556.295
=0.27581596

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=275.655/1670.033
=0.16505961

OK Biotech Co's gross margin of this year was 0.27581596. OK Biotech Co's gross margin of last year was 0.16505961. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=1556.295/3695.319
=0.42115309

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1670.033/3067.358
=0.54445324

OK Biotech Co's asset turnover of this year was 0.42115309. OK Biotech Co's asset turnover of last year was 0.54445324. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OK Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
OK Biotech Co (TPE:4155) has a Piotroski F-Score of 5 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OK Biotech Co and its competitors. This is near median its historical median of 5.00. Over the past decade, OK Biotech Co's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, OK Biotech Co ranks #282 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is OK Biotech Co's Piotroski F-Score too high?
OK Biotech Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. OK Biotech Co's value of 5 is 0% at this industry median. Based on the distribution chart, OK Biotech Co ranks #282 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #282 out of 805 companies for Piotroski F-Score. This puts OK Biotech Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. OK Biotech Co's value of 5 is 0% at this benchmark. Historically, OK Biotech Co's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, OK Biotech Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.27, compared to a current price of NT$14.45 — trading 47% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Devices & Instruments industry median of 5.00. OK Biotech Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current Piotroski F-Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OK Biotech Co (TPE:4155) Overvalued in 2026?

Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued. The current stock price of NT$14.45 is trading 47% below its estimated GF Value™ of NT$27.27. GuruFocus considers OK Biotech Co to be Possible Value Trap.

Key valuation signals for TPE:4155:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: NT$27.27 vs. price of NT$14.45 (47% below fair value)
  • GF Score™: 61/100 with 7 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#282 of 805)

No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OK Biotech Co Business Description

Address Gongdao 5th Road, Section 2, No. 91, Hsinchu, TWN, 30070
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
61GF Score

Get the complete analysis for TPE:4155

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$14.45
Price
NT$27.27
GF Value